Payden & Rygel Eli Lilly & CO Transaction History

Payden & Rygel

$1.3 Billion
Q3 2024

A detailed history of Payden & Rygel transactions in Eli Lilly & CO stock. As of the latest transaction made, Payden & Rygel holds 12,520 shares of LLY stock, worth $9.75 Million. This represents 0.86% of its overall portfolio holdings.

Number of Shares

12,520

Previous 24,220 48.31%

Holding current value

$9.75 Million

Previous $21.9 Million 49.42%

% of portfolio

0.86%

Previous 1.77%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 08, 2024	SELL	$772.14 - $960.02 $9.03 Million - $11.2 Million	-11,700 Reduced 48.31%	12,520 $11.1 Million
Q2 2024 Oct 07, 2024	SELL	$724.87 - $909.04 $4.13 Million - $5.18 Million	-5,700 Reduced 19.05%	24,220 $21.9 Million
Q1 2024 Oct 08, 2024	BUY	$592.2 - $792.28 $1.36 Million - $1.82 Million	2,300 Added 9.5%	26,520 $20.6 Million
Q4 2023 Feb 12, 2024	SELL	$525.19 - $619.13 $420,152 - $495,304	-800 Reduced 2.6%	29,920 $17.4 Million
Q2 2023 Aug 10, 2023	SELL	$350.74 - $468.98 $26.2 Million - $35 Million	-74,610 Reduced 70.83%	30,720 $14.4 Million
Q1 2023 May 10, 2023	SELL	$310.63 - $364.82 $4.53 Million - $5.32 Million	-14,570 Reduced 12.15%	105,330 $36.2 Million
Q4 2022 Feb 13, 2023	SELL	$321.55 - $374.67 $9.39 Million - $10.9 Million	-29,200 Reduced 19.58%	119,900 $43.9 Million
Q3 2022 Nov 10, 2022	SELL	$296.48 - $337.87 $1.07 Million - $1.22 Million	-3,600 Reduced 2.36%	149,100 $48.2 Million
Q2 2022 Aug 12, 2022	SELL	$278.73 - $327.27 $90,587 - $106,362	-325 Reduced 0.21%	152,700 $49.5 Million
Q1 2022 Apr 13, 2022	BUY	$234.69 - $291.66 $1.2 Million - $1.49 Million	5,100 Added 3.45%	153,025 $43.8 Million
Q4 2021 Feb 11, 2022	SELL	$224.85 - $279.04 $404,730 - $502,272	-1,800 Reduced 1.2%	147,925 $40.9 Million
Q3 2021 Nov 15, 2021	BUY	$221.6 - $272.71 $7.2 Million - $8.86 Million	32,500 Added 27.72%	149,725 $34.6 Million
Q2 2021 Aug 06, 2021	BUY	$180.55 - $233.54 $19.5 Million - $25.2 Million	107,728 Added 1134.34%	117,225 $26.9 Million
Q1 2021 May 13, 2021	SELL	$164.32 - $212.72 $38 Million - $49.2 Million	-231,103 Reduced 96.05%	9,497 $1.77 Million
Q3 2020 Nov 10, 2020	BUY	$146.22 - $169.13 $1.07 Million - $1.23 Million	7,300 Added 3.13%	240,600 $35.6 Million
Q2 2020 Aug 12, 2020	SELL	$136.42 - $164.18 $11.6 Million - $13.9 Million	-84,900 Reduced 26.68%	233,300 $38.3 Million
Q1 2020 May 04, 2020	SELL	$119.05 - $147.35 $2.77 Million - $3.43 Million	-23,256 Reduced 6.81%	318,200 $44.1 Million
Q4 2019 Jan 31, 2020	BUY	$106.92 - $132.43 $7.14 Million - $8.85 Million	66,800 Added 24.32%	341,456 $44.9 Million
Q3 2019 Oct 30, 2019	BUY	$106.79 - $116.16 $892,764 - $971,097	8,360 Added 3.14%	274,656 $30.7 Million
Q2 2019 Aug 06, 2019	BUY	$110.79 - $129.32 $4.81 Million - $5.61 Million	43,400 Added 19.47%	266,296 $29.5 Million
Q1 2019 May 08, 2019	SELL	$111.31 - $131.02 $634,912 - $747,338	-5,704 Reduced 2.5%	222,896 $28.9 Million
Q4 2018 Jan 25, 2019	BUY	$105.9 - $118.64 $868,380 - $972,848	8,200 Added 3.72%	228,600 $26.5 Million
Q3 2018 Nov 07, 2018	SELL	$85.86 - $107.31 $231,822 - $289,737	-2,700 Reduced 1.21%	220,400 $23.7 Million
Q1 2018 May 09, 2018	BUY	$74.21 - $87.6 $2.02 Million - $2.38 Million	27,200 Added 13.88%	223,100 $17.3 Million
Q3 2017 Nov 14, 2017	BUY	$77.07 - $85.54 $15.1 Million - $16.8 Million	195,900	195,900 $16.8 Million

Others Institutions Holding LLY

# of Institutions

4,010

Shares Held

752M

Call Options Held

8.27M

Put Options Held

10.5M

View Full List

About ELI LILLY & Co

Ticker LLY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 950,174,976
Market Cap $740B
Description
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...

More about LLY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Payden & Rygel, based on Form 13F filings with the SEC.

News

Stay updated on Payden & Rygel with notifications on news.

Account